At a glance
ClinicalIndex Comparison RecordPhase 4Completed· 770 enrolled
Drug / intervention
Tadalafil +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Impact of Tadalafil (LY450190) Once a Day or Tadalafil on Demand Compared to Sildenafil Citrate on Demand on Treatment Discontinuation in Patients With Erectile Dysfunction Who Are naïve to PDE5 Inhibitors
In Brief
A Phase 4 clinical trial evaluating Tadalafil and Sildenafil Citrate for Erectile Dysfunction. Completed, enrolled 770 participants across 45 sites in 8 countries.
Detailed Summary
The purpose of this study is to investigate if treatment in erectile dysfunction with a long-acting drug (Tadalafil) taken once a day or taken as needed results in a longer treatment adherence and better long term outcomes (over 24 weeks), compared with a short-acting drug (Sildenafil Citrate) taken as needed.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsErectile Dysfunction
CountriesFrance, Germany, Greece, Poland, Portugal, Romania, Spain, United Kingdom
Collaborators--
Timeline
Phase 4CompletedFinished
20102011201220132014201520162017201820192020202120222023202420252026
Enrollment StartMay 2010
First PostedMay 2010
Primary CompletionJun 2011
TodayJul 2026
First PostedMay 13, 2010
Enrollment StartMay 1, 2010
Primary CompletionJun 1, 2011
TodayJul 2, 2026
Enrollment to primary: 1.1 yearsPosted 16.1 years ago
Interventions
Tadalafildrug
Administered orally for 24 weeks.
Sildenafil Citratedrug
Administered orally for 24 weeks.